Clinical Trial Results: Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ribociclib + letrozole as first-line in HR+ HER2-negative advanced breast cancer, with alpelisib + fulvestrant as second-line for PIK3C…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Alpelisib (alpelisib)
• Fulvestrant (fulvestrant)
• Letrozole (letrozole)
• Ribociclib (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 3 | Status: TERMINATED | Results posted: 2026-07-10